Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Denise Shortino"'
Publikováno v:
Drugs in Context, Vol 11, Pp 1-12 (2022)
Background: Few randomized controlled trials evaluate the long-term efficacy and safety of pharmacotherapy for overactive bladder (OAB). This network meta-analysis compares the long-term (52-week) efficacy and safety of vibegron, mirabegron and antic
Externí odkaz:
https://doaj.org/article/38234546bf3741fa8c2a5ff92b695a47
Autor:
Peiying Zuo, Jon Collins, Malek Okour, Aline Barth, Denise Shortino, Phillip Yates, Grace Roberts, Helen A. Watson, Amanda Peppercorn, Mohammad Hossain
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 1, Pp 157-168 (2020)
Zanamivir is a potent and highly selective inhibitor of influenza neuraminidase in which the inhibition of this enzyme prevents the virus from infecting other cells and specifically prevents release of the new virion from the host cell membrane. It i
Externí odkaz:
https://doaj.org/article/26aa4ebc79db4540828e09fb7ca0c5b5
Autor:
James G Krueger, Mayte Suárez-Fariñas, Inna Cueto, Artemis Khacherian, Robert Matheson, Lawrence C Parish, Craig Leonardi, Denise Shortino, Akanksha Gupta, Jonathan Haddad, George P Vlasuk, Eric W Jacobson
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0142081 (2015)
Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. We randomized 40 patients with moderate-to-severe psoriasis (4:1) to three escalati
Externí odkaz:
https://doaj.org/article/9e19d739bed14e038b7414b6243efab0
Autor:
Denise Shortino, Thomas Rhodes, Cynthia J. Girman, Elizabeth Thomas, Michael J. Kennelly, Paul N. Mudd
Publikováno v:
Advances in Therapy
Background In the absence of head-to-head trials, we performed an indirect treatment comparison of the β3-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB). Methods PubMed, Embase, and Cochrane Library were sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f64ee91efc82141ad2df07410a5250
https://doi.org/10.1007/s12325-021-01902-8
https://doi.org/10.1007/s12325-021-01902-8
Autor:
Jeffrey Frankel, David R. Staskin, Susann Varano, Rachael Jankowich, Denise Shortino, Paul N. Mudd
Publikováno v:
Drugs & Aging
Background Overactive bladder (OAB) is common among older adults. The efficacy and safety of vibegron for the treatment of OAB were demonstrated in the international, phase III EMPOWUR trial. This subpopulation analysis from EMPOWUR assessed the effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f13652957bd5e6219fee7bf4b3d0785
http://europepmc.org/articles/PMC7882560
http://europepmc.org/articles/PMC7882560
Autor:
Brian E. Lacy, Jennifer King, Denise Shortino, Chris Schaumburg, Cornelia Haag‐Molkenteller, William D. Chey
Publikováno v:
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility SocietyREFERENCES. 34(12)
Preclinical and clinical studies suggest that βAdult women with predominant-diarrhea IBS (IBS-D) or with mixed diarrhea/constipation (IBS-M), diagnosed using Rome IV criteria, were randomized 1:1 to receive once-daily vibegron 75 mg or placebo for 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3751ca97de487d8be10fca54f5b0b760
https://pubmed.ncbi.nlm.nih.gov/35975404
https://pubmed.ncbi.nlm.nih.gov/35975404
Autor:
Phillip J. Yates, Malek Okour, Jon Collins, Grace Roberts, Peiying Zuo, Helen A. Watson, Denise Shortino, Aline Barth, Mohammad Hossain, Amanda Peppercorn
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 1, Pp 157-168 (2020)
Clinical and Translational Science
Clinical and Translational Science
Zanamivir is a potent and highly selective inhibitor of influenza neuraminidase in which the inhibition of this enzyme prevents the virus from infecting other cells and specifically prevents release of the new virion from the host cell membrane. It i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa5563b82f9d824958d5a466ac2e44a
https://doaj.org/article/26aa4ebc79db4540828e09fb7ca0c5b5
https://doaj.org/article/26aa4ebc79db4540828e09fb7ca0c5b5
Autor:
Michael Kennelly, David R. Staskin, Paul N. Mudd, Matt T. Rosenberg, Denise Shortino, Susann Varano, Jeffrey Frankel, Rachael Jankowich, Diane K. Newman
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Overactive bladder (OAB) is characterized by urinary urgency, often accompanied by frequency and nocturia, with or without urge urinary incontinence (UUI), referred to as...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::851091d4e2b0ab0fbd7a0b3ac0402923
https://doi.org/10.1097/ju.0000000000002103.15
https://doi.org/10.1097/ju.0000000000002103.15
Autor:
Jeffrey Frankel, David Staskin, Susann Varano, Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Rachael A. Jankowich, Denise Shortino, Paul N. Mudd, Cynthia J. Girman
Publikováno v:
Advances in therapy. 39(2)
Reductions in bothersome symptoms of overactive bladder (OAB) demonstrate improvement in clinical trials, but patient perception of meaningfulness of such improvement is lacking. In the 12-week phase 3 EMPOWUR trial, vibegron significantly reduced av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ba8e33d19b9a5b2ebc4d5fa88b1159
https://pubmed.ncbi.nlm.nih.gov/34921665
https://pubmed.ncbi.nlm.nih.gov/34921665
Autor:
Jeffrey Frankel, Susann Varano, Denise Shortino, Paul N. Mudd, David R. Staskin, Rachael Jankowich
Publikováno v:
International Journal of Clinical Practice
Background Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β3‐adrenergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomised, double‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d3fd90f6cfa035be4373072df3fad0
http://europepmc.org/articles/PMC8244055
http://europepmc.org/articles/PMC8244055